Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
Status:
Withdrawn
Trial end date:
2020-09-03
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare
endocrine cancers that have spread from where they started to nearby tissue or lymph nodes
(locally advanced), spread to other places in the body (metastatic), or cannot be removed by
surgery (unresectable). Radioactive drugs, such as 177Lu-DOTATATE, may carry radiation
directly to cancer cells and not harm normal cells. 177Lu-DOTATATE may help to control
endocrine cancers compared to standard treatment.